I. Executive Summary Background The 5 years since the publication of the first International
Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed …

Chronic rhinosinusitis (CRS) affects up to 12% of the general population and is traditionally
divided into two main phenotypic subsets, based on the presence of nasal polyps …

Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE
hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has …

Background Endoscopic sinus surgery (ESS) is a common operation for patients with
chronic rhinosinusitis with nasal polyps (CRSwNP) when medical therapy alone is …

Importance Staphylococcus aureusinfections are associated with recalcitrant chronic
rhinosinusitis (CRS). The emerging threat of multidrug-resistantS aureusinfections has …

Background In the Phase III SYNAPSE study, mepolizumab reduced nasal polyp (NP) size
and nasal obstruction in chronic rhinosinusitis with NP (CRSwNP). Objective To assess the …

Background Comparative effectiveness research between endoscopic sinus surgery (ESS)
and biologic therapy for severe chronic rhinosinusitis with nasal polyposis (CRSwNP) is a …

Rationale: Elexacaftor, tezacaftor, and ivacaftor (ETI) in triple combination improves
pulmonary health for people with cystic fibrosis (PwCF). However, its impact on objective …

Purpose Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin.
In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized …